UV Flu Technologies is a manufacturer of the finest air purification systems in the world and is committed to providing clean air to improve health and prevent the spread of disease. Its proven germicidal air purification technology removes and kills bacteria with more than 99% efficiency.
The Company’s strategic differentiators include excellent independent test results proving the effectiveness and safety of its products, and proprietary design.
To drive growth UV Flu is working to gain market share selling to the U.S. commercial healthcare sector, pursue strategic alliances with medical product distributors, develop additional air quality products, and acquire companies and products with complementary offerings.
The Company has developed relationships with key hospital and nursing home administrators, medical equipment distributors and medical sales representatives.
The Company has filed U.S. Patent No. 6939397 with 43 claims covering its innovative removable cartridge, housing, UV chamber, UV radiation source and baffle technology.
UV Flu’s products are environmentally friendly. The energy efficient system does not use or produce ozone, uses less energy than a 100 watt light bulb and can qualify for Green Building programs.
The unique replaceable cartridge design provides a continuous revenue stream throughout the product life cycle.
The market for air purification equipment has been gaining momentum as a result of rising concerns over IAQ and increasing health consciousness among consumers. Products within this group that until recently had been viewed as a luxury are now found in an increasing number of homes and commercial work spaces. As a result, the North American air purification equipment market will expand significantly. (Global Industry Analysts, “Air Purification Equipment Market”, February 2009).The U.S. IAQ market generated $7.7 billion in 2008, with the equipment segment accounting for $3.6 billion. Continuing media attention given to the health effects of toxic mold, the outbreak of infectious diseases such as swine flu, and the increase in chronic respiratory diseases such as asthma have resulted in new interest in, and attention to, indoor air quality. Building owners and operators are expected to purchase growing quantities of IAQ-related equipment and services in the hope of reducing or eliminating these contaminants from their buildings. (BCC Research, “U.S. Indoor Air Quality Market”, August 2009).
Employers have incentive to keep workers healthy. 425 million sick days were taken in 2008, costing an estimated $60 billion in lost productivity. “Presenteeism,” a new term coined for employees working while unhealthy, is even worse for employers and the healthcare system, costing approximately $160 billion annually in lost productivity. (Kalorama Information, “The Market for Wellness Programs”, September 2009).
UV Flu is focused initially on the commercial market, targeting medical, hospitality and commercial building customers. UV Flu is first selling and leasing its products directly or through distributors to medical accounts including hospitals, doctor and dentist offices, clinics and nursing homes. Projections for first year shipments are the result of interaction with key hospital and nursing home administrators as well as medical equipment distributors and medical sales representatives.
The Company is leveraging longstanding contacts within the healthcare industry to drive placement. The team developed strong contacts with a number of large hospitals during its in-field product testing program.
Click here to view our information posted within the EDGAR Database of the U.S. Securities and Exchange Commission.
Click here Click here to view our Section 16 Filings.